Home World News Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory...

Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy

February 19, 2026

288

Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study